法国652例HIV血清学阴性个体隐球菌病的特征:2005-2020年横断面观察性研究
该研究纳入法国隐球菌病监测网络中2005至2020年HIV血清学阴性的隐球菌病 incident 病例,比较不同基础疾病患者的特征、表现、隐球菌抗原结果及诱导抗真菌治疗,分析90天死亡相关因素。结果显示恶性肿瘤、实体器官移植、其他免疫抑制状态及无基础疾病者分别占32.1%、19.9%、31.3%和16.7%,播散性感染占63.3%,粗90天病死率为27.2%,氟胞嘧啶联合多烯类治疗与较低90天死亡率相关。
要点
- HIV血清学阴性隐球菌病患者中,恶性肿瘤占32.1%,实体器官移植占19.9%,其他免疫抑制状态占31.3%,无基础疾病者占16.7%。
- 播散性感染占63.3%(413/652),孤立性肺部感染占25.3%(165/652);实体器官移植患者最易出现播散性感染和血清隐球菌抗原阳性。
- 粗90天病死率为27.2%(95%CI 23.5%-31.1%);年龄≥60岁、脑膜炎/真菌血症及恶性肿瘤与较高90天死亡率相关。
核心结论
- HIV血清学阴性隐球菌病患者涵盖多种基础疾病,其表现和结局不同,需要个体化的诊断和管理方法。
研究设计与样本
- 研究为横断面观察性研究,纳入法国隐球菌病监测网络2005至2020年HIV血清学阴性的隐球菌病 incident 病例,共652例。
主要发现
- 652例中,恶性肿瘤209例(32.1%),实体器官移植130例(19.9%),其他免疫抑制状态204例(31.3%),无报告基础因素109例(16.7%)。
- 最常见表现为播散性感染(63.3%,413/652)和孤立性肺部感染(25.3%,165/652);实体器官移植患者最易出现播散性感染和血清隐球菌抗原阳性。
- 恶性肿瘤患者年龄较大,且播散性感染时接受含氟胞嘧啶方案的比例低于其他患者(58.7%,78/133 vs. 73.2%,194/265;p=0.029)。
- 粗90天病死率为27.2%(95%CI 23.5%-31.1%);年龄≥60岁(aOR 2.75 [1.78-4.26];p<0.001)、脑膜炎/真菌血症(aOR 4.79 [1.80-12.7];p=0.002)和恶性肿瘤(aOR 2.4 [1.14-5.07];p=0.02)与较高90天死亡率相关。
- 接受氟胞嘧啶联合多烯类治疗与较低90天死亡率相关(多变量分析aOR 0.40 [0.23-0.71];p=0.002;逆概率治疗加权分析aOR 0.45 [0.25-0.80];p=0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to describe features and outcomes of cryptococcosis among HIV-seronegative individuals in a large surveillance network for cryptococcosis in France. METHODS: We included incident cases of cryptococcosis in HIV-seronegative individuals from 2005 to 2020. We compared patient characteristics, disease presentations, cryptococcal antigen results, and induction antifungal treatments according to underlying disease. We examined factors associated with 90-day mortality. Among patients with disseminated infections, we investigated whether receipt of flucytosine and polyene combination was associated with lower mortality. RESULTS: Among 652 individuals, 209 (32.1%) had malignancy, 130 (19.9%) were solid-organ transplant recipients, 204 (31.3%) had other immunocompromising conditions, and 109 (16.7%) had no reported underlying factor. The commonest presentations were disseminated infections (63.3%, 413/652) and isolated pulmonary infections (25.3%, 165/652). Solid-organ transplant patients were most likely to have disseminated infections and a positive serum cryptococcal antigen result. Patients with malignancy were older and less likely to receive a flucytosine-containing regimen for disseminated infections than others (58.7%, 78/133 vs. 73.2%, 194/265; p 0.029). The crude 90-day case-fatality ratio was 27.2% (95% CI, 23.5%-31.1%). Age ≥60 years (aOR: 2.75 [1.78-4.26]; p < 0.001), meningitis/fungaemia (aOR: 4.79 [1.80-12.7]; p 0.002), and malignancy (aOR: 2.4 [1.14-5.07]; p 0.02) were associated with higher 90-day mortality. Receipt of flucytosine and polyene combination was associated with lower 90-day mortality (aOR: 0.40 [0.23-0.71]; p 0.002) in multivariable analysis and inverse probability of treatment weighted analysis (aOR: 0.45 [0.25-0.80]; p 0.006). DISCUSSION: HIV-seronegative individuals with cryptococcosis comprise a wide range of underlying conditions with different presentations and outcomes, requiring a tailored approach to diagnosis and management.
引用
- Paccoud O, Desnos-Ollivier M, Persat F, et al. Features of cryptococcosis among 652 HIV-seronegative individuals in France: a cross-sectional observational study (2005-2020). Clin Microbiol Infect. 2024. PMID: 38556212. doi:10.1016/j.cmi.2024.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。